TherapeuticsMD Inc. (NASDAQ:TXMD) stock is down 10% in a week. Recently the company reported its financial results forQ2 2021 ended June 30, 2021. The company reported net product revenue of ANNOCERA of $9.6 million, increasing $7.7 million from Q2 2020. There were around 7,200 ANNOVERA prescriptions reported during the quarter, a 202% YoY increase and a 17% QoQ increase.
Most importantly, refill rates are still strong at 50% for qualifying patients. IMVEXXY net revenue was $9.8 million with 117,000 prescriptions, while BIJUVA reported net revenue of $2.2 million with 31,900 prescriptions dispensed during the quarter.
CEO Robert Finizio stated that the company continues to experience solid progress as per expectations related to IMVEXXY and ANNOVERA to boost net margins, prescription growth, and patient access. Most importantly, the company is witnessing enhanced healthcare providers’ access and expansion of relations in telemedicine. In addition, Finizio said they are evaluating vitacare investment, including possible minority stake sale, which will offer non-dilutive capital to shareholders. Therefore, in weeks to come, TXMD is a stock to watch.
On Thursday, TXMD stock rose 3% at $0.94 with more than 6.90 million shares, compared to its average volume of 5.85 million shares. The stock has moved within a range of $0.9250 – 0.9636 after opening the trade at $0.93.